A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers

Cancer Letters

Volumn 130, Issue 1-2, 1998, Pages 93-101

  Lingfei, Kong ^a   Pingzhang, Ying ^a   Zhengguo, Liu ^a   Jianhua, Gen ^a   Yaowu, Zhao ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

cdk4; CyclinD1; Non small cell lung cancer; p16; pRb

Indexed keywords

CYCLIN D1; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN KINASE; PROTEIN P16;

ADENOCARCINOMA; ARTICLE; CELL DIFFERENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN;

EID: 0032516632     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00115-3     Document Type: Article

References (17)

1. Otterson G., Lin A., Kay F. Genetic etiology of lung cancer. Oncol. Huntingt. 6(9):1992;97-111.
2. Kratzke R.A., Greatens T.M., Rubins J.B.et al. Rb and p16INK4a in resected non-small cell lung tumors. Cancer Res. 56(15):1996;3415-3420.
3. Hollstein M., Sidransky D., Vogelstein B.et al. P53 mutations in human cancers. Science. 253:1991;49-53.
4. Paul N. Ordering S phase and M phase in the cell cycle. Cell. 79:1994;547-550.
5. Kamb A., Gruis N.A., Weaver J.F.et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
6. Koh J., Enders G.H., Dynlacht B.D.et al. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 375:1995;506-510.
7. Okamoto A., Demetrick D.J., Spillare E.A.et al. Mutations and altered expression of p16ink4 in human cancer. Proc. Natl. Acad. Sci. USA. 91:1994;11045-11049.
8. Geradts J., Kratzke R.A., Niehans G.A.et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 product p16 in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 55:1995;6006-6011.
9. De V.S., Miller C.W., Takeuchi S.et al. Alterations of CDKN2 in non-small cell lung cancer. Genes Chromosomes Cancer. 14(3):1995;164-170.
10. Nakagawa K., Conras N.K., Williams J.P.et al. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell cancer and association with advanced stage. Oncogene. 11(9):1995;1843-1851.
11. Otterson G.A., Khleif S.N., Chen W.et al. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene. 11(6):1995;1211-1216.
12. Li Y., Nichols M.A., Shay J.W.et al. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 54:1994;6075-6082.
13. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
14. Wolfel T., Hauer M., Schneider J.et al. A p16 insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1995;1281-1284.
15. Sakaguchi M., Fujii Y., Hirabayashi H.et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int. J. Cancer. 65(4):1996;442-445.
16. Mirsudomi T., Takahashi T. Genetic abnormalities in lung cancer and their prognostic implications. Gan To Kagaku Ryoho. 23(8):1996;990-996.
17. Kratzke R.A., Shimizu E., Kaye F.J. Oncogenes in human lung cancer. Cancer Treat. Res. 63:1992;61-85.